Systemic/oral corticosteroids (OCS) have been used for decades in the management of
acute asthma exacerbations and chronically in patients with uncontrolled severe asthma …

BACKGROUND: Long-term oral corticosteroid (OCS) therapy is associated with significant
burden on patients and healthcare resources; treatments that may help reduce their use are …

Background: Long-term oral corticosteroid (OCS) therapy and related adverse events are
associated with a significant burden on patients and healthcare resources. Methods: This …

BACKGROUND: Asthma guidelines advocate maintaining asthma control while minimizing
corticosteroid exposure. OBJECTIVE: To assess the reduction in corticosteroid burden …

Objective Patients with severe asthma require high-dose inhaled corticosteroids, with or
without add-on treatments, to maintain asthma control. Because symptom control remains …

Background Oral corticosteroids (OCS) are commonly administered in patients with severe
persistent allergic asthma. Despite their efficacy, they are associated with a wide variety of …

There are now several monoclonal antibody (mAb) therapies (“biologics”) available to treat
severe asthma. Omalizumab is an anti-IgE mAb and is licensed in severe allergic asthma …

BACKGROUND: A novel anti‐immunoglobulin E (anti‐IgE) therapy for asthma, omalizumab,
has been approved for use in Canada. OBJECTIVE: To review the basic and clinical data for …

Introduction Data on the clinical efficacy and remodeling of omalizumab therapy in patients
on oral corticosteroids (OC) are limited. Objective The purpose of the study is to show that in …

Background Patients with severe asthma are often inadequately controlled on existing anti‐
asthma therapy, constituting an unmet clinical need. Objective This randomized, double …